e-learning
resources
Virtual 2021
05.09.2021
Biomarkers for the management of bronchial obstructive diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum periostin and eotaxin-2 as promising biomarkers in asthmatic smokers.
S. Farghly (Assiut, Egypt), A. El-Karn (Assiut, Egypt), M. Sherif (Assiut, Egypt), M. Seddik (Assiut, Egypt), S. Abdelgayed (Assiut, Egypt), M. Abdelghany (Assiut, Egypt)
Source:
Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases
Session:
Biomarkers for the management of bronchial obstructive diseases
Session type:
E-poster
Number:
1135
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Farghly (Assiut, Egypt), A. El-Karn (Assiut, Egypt), M. Sherif (Assiut, Egypt), M. Seddik (Assiut, Egypt), S. Abdelgayed (Assiut, Egypt), M. Abdelghany (Assiut, Egypt). Serum periostin and eotaxin-2 as promising biomarkers in asthmatic smokers.. 1135
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Serum periostin is not a good biomarker to identify Th2-driven inflammation in COPD
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Serum neopterin and IL-6 as biomarkers in patients with COPD.
Source: International Congress 2017 – Novel molecular and genetic targets in COPD
Year: 2017
Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD
Source: International Congress 2017 – COPD biomarkers
Year: 2017
The serum YKL-40 is a useful biomarker for asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
Cigarette smoking induced elevated CXCL5 levels in BALF and plasma of patients with COPD
Source: International Congress 2018 – COPD: novel pathological mechanisms in the airway epithelium
Year: 2018
Osteopontin expression is increased in serum, BAL and bronchial tissue of asymptomatic smokers
Source: Annual Congress 2009 - COPD and asthma - from the cell to the clinic
Year: 2009
Visfatin as a possible serum biomarker in COPD
Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases
Year: 2019
Serum periostin but not airway
POSTN
expression is reduced in smokers with asthma
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
Osteopontin and IL17 concentration in serum and breath condensates of asthmatic children in Greece
Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma
Year: 2009
Age related alterations in sputum and plasma MMP-9 and TIMP-1 levels in healthy non-smokers and smokers
Source: Annual Congress 2010 - Novel markers of lung injury
Year: 2010
Cytokine expression in induced sputum in smokers with asthma or COPD and in healthy smokers
Source: Eur Respir J 2003; 22: Suppl. 45, 392s
Year: 2003
Elevated serum IL-12 and IL-18 levels in patients with bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 424s
Year: 2002
Serum G-CSF is a non-invasive biomarker classifying bacterial/neutrophilic COPD exacerbations
Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Year: 2020
PP102 – A serum biomarker reflecting human neutrophil elastase degraded calprotectin is elevated in COPD and IPF
Source: ERS Lung Science Conference 2021
Year: 2021
Serum and sputum interleukin-8: comparison between normal and allergic asthmatics children
Source: Eur Respir J 2003; 22: Suppl. 45, 175s
Year: 2003
Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis
Source: International Congress 2017 – Silicosis has not gone away
Year: 2017
Lebrikizumab reduces serum periostin in asthma patients with elevated baseline periostin
Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use
Year: 2012
Serum hyaluronate: A new biomarker of passive smoking-induced lung injury in asthmatic patients
Source: Annual Congress 2010 - Innovations in the assessment of airway diseases
Year: 2010
Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children
Source: Eur Respir J 2003; 21: 616-620
Year: 2003
Increased levels of osteopontin in sputum supernatant in smoking asthma
Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept